|
1
|
Marik PE: Propofol: an immunomodulating
agent. Pharmacotherapy. 25:S28–S33. 2005. View Article : Google Scholar
|
|
2
|
Tramèr M, Moore A and McQuay H: Propofol
anaesthesia and postoperative nausea and vomiting: quantitative
systematic review of randomized controlled studies. Br J Anaesth.
78:247–255. 1997.PubMed/NCBI
|
|
3
|
Schaer H: Propofol infusion for the
maintenance of short-term anesthesia. Anaesthesist. 37:187–192.
1988.(In German).
|
|
4
|
Wilson C, Canning P and Caravati EM: The
abuse potential of propofol. Clin Toxicol (Phila). 48:165–170.
2010. View Article : Google Scholar
|
|
5
|
Kotani Y, Shimazawa M, Yoshimura S, Iwama
T and Hara H: The experimental and clinical pharmacology of
propofol, an anesthetic agent with neuroprotective properties. CNS
Neurosci Ther. 14:95–106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalyuzhny AE, Dooyema J and Wessendorf MW:
Opioid- and GABA(A)-receptors are co-expressed by neurons in rat
brain. Neuroreport. 11:2625–2628. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang G, Chen W and Marvizón JC: Src
family kinases mediate the inhibition of substance P release in the
rat spinal cord by μ-opioid receptors and GABA(B) receptors, but
not α2 adrenergic receptors. Eur J Neurosci. 32:963–973.
2010.PubMed/NCBI
|
|
8
|
Mao J: NMDA and opioid receptors: their
interactions in antinociception, tolerance and neuroplasticity.
Brain Res Brain Res Rev. 30:289–304. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Hasani R and Bruchas MR: Molecular
mechanisms of opioid receptor-dependent signaling and behavior.
Anesthesiology. 115:1363–1381. 2011.PubMed/NCBI
|
|
10
|
Mayer P and Höllt V: Pharmacogenetics of
opioid receptors and addiction. Pharmacogenet Genomics. 16:1–7.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Toro R, Baiula M and Spampinato S:
Expression of the repressor element-1 silencing transcription
factor (REST) is influenced by insulin-like growth factor-I in
differentiating human neuroblastoma cells. Eur J Neurosci.
21:46–58. 2005.PubMed/NCBI
|
|
12
|
Zhang Y, Wang D, Johnson AD, Papp AC and
Sadée W: Allelic expression imbalance of human mu opioid receptor
(OPRM1) caused by variant A118G. J Biol Chem. 280:32618–32624.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Munson PJ and Rodbard D: Ligand: a
versatile computerized approach for characterization of
ligand-binding systems. Anal Biochem. 107:220–239. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guarino G and Spampinato S: Nandrolone
decreases mu opioid receptor expression in SH-SY5Y human
neuroblastoma cells. Neuroreport. 19:1131–1135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petroni D, Tsai J, Mondal D and George W:
Attenuation of low dose methylmercury and glutamate
induced-cytotoxicity and tau phosphorylation by an
N-methyl-D-aspartate antagonist in human neuroblastoma (SHSY5Y)
cells. Environ Toxicol. Oct 5–2011.(Epub ahead of print).
View Article : Google Scholar
|
|
16
|
Massone S, Vassallo I, Fiorino G, et al:
17A, a novel non-coding RNA, regulates GABA B alternative splicing
and signaling in response to inflammatory stimuli and in Alzheimer
disease. Neurobiol Dis. 41:308–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gianoulakis C: Endogenous opioids and
addiction to alcohol and other drugs of abuse. Curr Top Med Chem.
4:39–50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
López-Moreno JA, López-Jiménez A, Gorriti
MA and de Fonseca FR: Functional interactions between endogenous
cannabinoid and opioid systems: focus on alcohol, genetics and
drug-addicted behaviors. Curr Drug Targets. 11:406–428.
2010.PubMed/NCBI
|
|
19
|
Berrendero F, Robledo P, Trigo JM,
Martín-García E and Maldonado R: Neurobiological mechanisms
involved in nicotine dependence and reward: participation of the
endogenous opioid system. Neurosci Biobehav Rev. 35:220–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ray LA, Barr CS, Blendy JA, Oslin D,
Goldman D and Anton RF: The role of the Asn40Asp polymorphism of
the mu opioid receptor gene (OPRM1) on alcoholism etiology and
treatment: a critical review. Alcohol Clin Exp Res. 36:385–394.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carrasco G, Molina R, Costa J, Soler JM
and Cabré L: Propofol vs midazolam in short-, medium-, and
long-term sedation of critically ill patients: a cost-benefit
analysis. Chest. 103:557–564. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miller LJ and Wiles-Pfeifler R: Propofol
for the long-term sedation of a critically ill patient. Am J Crit
Care. 7:73–76. 1998.PubMed/NCBI
|
|
23
|
Boyle WA, Shear JM, White PF and Schuller
D: Long-term sedative infusion in the intensive care unit: propofol
vs midazolam. J Drug Dev. 4(Suppl): S43–S45. 1991.
|
|
24
|
Cammarano WB, Pittet JF, Weitz S,
Schlobohm RM and Marks JD: Acute withdrawal syndrome related to the
administration of analgesic and sedative medications in adult
intensive care unit patients. Crit Care Med. 26:676–684. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Au J, Walker S and Scott DHT: Withdrawal
syndrome after propofol infusion. Anaesthesia. 45:741–742. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McAuliffe PF, Gold MS, Bajpai L, et al:
Second-hand exposure to aerosolized intravenous anesthetics
propofol and fentanyl may cause sensitization and subsequent opiate
addiction among anesthesiologists and surgeons. Med Hypotheses.
66:874–882. 2006. View Article : Google Scholar
|
|
27
|
Kashiwagi M, Osaka Y, Onimaru H and Takeda
J: Optical imaging of propofol-induced central respiratory
depression in medulla-spinal cord preparations from newborn rats.
Clin Exp Pharmacol Physiol. Jan 19–2011.(Epub ahead of print).
View Article : Google Scholar
|
